China Medical System Holdings Ltd
HKEX:867
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
China Medical System Holdings Ltd
Free Cash Flow
China Medical System Holdings Ltd
Free Cash Flow Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Free Cash Flow | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Medical System Holdings Ltd
HKEX:867
|
Free Cash Flow
¥244m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
-7%
|
|
|
H
|
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
|
Free Cash Flow
¥4.5B
|
CAGR 3-Years
22%
|
CAGR 5-Years
36%
|
CAGR 10-Years
N/A
|
|
|
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
|
Free Cash Flow
¥8.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
46%
|
CAGR 10-Years
16%
|
|
|
Yunnan Baiyao Group Co Ltd
SZSE:000538
|
Free Cash Flow
¥4.1B
|
CAGR 3-Years
14%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
|
Zhejiang Nhu Co Ltd
SZSE:002001
|
Free Cash Flow
¥6.9B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
55%
|
CAGR 10-Years
N/A
|
|
|
S
|
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
|
Free Cash Flow
¥4B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
256%
|
CAGR 10-Years
N/A
|
|
China Medical System Holdings Ltd
Glance View
China Medical System Holdings Ltd., a notable player in the Chinese pharmaceutical landscape, has woven a strategy that cleverly integrates proprietary drug development with a robust marketing apparatus. Established in 1995 and headquartered in Shenzhen, the company has developed a knack for identifying pharmaceuticals and medical devices with promising potential. Their business model hinges on acquiring exclusive rights to a carefully curated portfolio of international products, which they then introduce to the burgeoning Chinese market. By leveraging their deep understanding of market dynamics and regulatory environments, they effectively roll out these products, ensuring that they meet local demand and adhere to high compliance standards. The company's revenue engine is powered predominantly by its dynamic sales and marketing network which spans across mainland China. They employ a multifaceted distribution model, partnering with an extensive range of hospitals and healthcare providers to facilitate widespread adoption of their products. But what truly sets China Medical System Holdings apart is its focus on products that are already well advanced within their lifecycle, minimizing the usual risks associated with early-stage pharmaceutical development. This strategic approach not only ensures steady cash flows but also reduces overhead costs associated with R&D, allowing them to reinvest profits into acquiring new products and expanding their market footprint. As such, their business thrives on a cycle of discernment and targeted expansion, positioning them as a formidable entity in the healthcare sector.
See Also
What is China Medical System Holdings Ltd's Free Cash Flow?
Free Cash Flow
244m
CNY
Based on the financial report for Dec 31, 2025, China Medical System Holdings Ltd's Free Cash Flow amounts to 244m CNY.
What is China Medical System Holdings Ltd's Free Cash Flow growth rate?
Free Cash Flow CAGR 10Y
-7%
Over the last year, the Free Cash Flow growth was -70%. The average annual Free Cash Flow growth rates for China Medical System Holdings Ltd have been -57% over the past three years , -36% over the past five years , and -7% over the past ten years .